CYCLERION THERAPEUTICS INC (CYCN) Stock Price & Overview
NASDAQ:CYCN • US23255M2044
The current stock price of CYCN is 1.42 USD. Today CYCN is down by -0.7%. In the past month the price increased by 16.39%. In the past year, price decreased by -43.87%.
CYCN Key Statistics
- Market Cap
- 5.581M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.76
- Dividend Yield
- N/A
CYCN Stock Performance
CYCN Stock Chart
CYCN Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CYCN. When comparing the yearly performance of all stocks, CYCN is a bad performer in the overall market: 86.28% of all stocks are doing better.
CYCN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYCN. CYCN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CYCN Earnings
On March 2, 2026 CYCN reported an EPS of -0.3 and a revenue of 880.00K.
CYCN Forecast & Estimates
7 analysts have analysed CYCN and the average price target is 8.16 USD. This implies a price increase of 474.65% is expected in the next year compared to the current price of 1.42.
For the next year, analysts expect an EPS growth of -12.58% and a revenue growth -43.9% for CYCN
CYCN Groups
Sector & Classification
CYCN Financial Highlights
Over the last trailing twelve months CYCN reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS increased by 46.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.11% | ||
| ROE | -23.06% | ||
| Debt/Equity | 0 |
CYCN Ownership
CYCN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.19 | 402.577B | ||
| AMGN | AMGEN INC | 16.11 | 203.574B | ||
| GILD | GILEAD SCIENCES INC | 16.43 | 181.247B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.66 | 125.079B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 81.897B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.52 | 42.495B | ||
| INSM | INSMED INC | N/A | 30.048B | ||
| BIIB | BIOGEN INC | 11.5 | 27.955B | ||
| NTRA | NATERA INC | N/A | 27.865B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.84 | 23.875B | ||
| MRNA | MODERNA INC | N/A | 22.105B | ||
| EXAS | EXACT SCIENCES CORP | 339.75 | 19.738B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.736B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CYCN
Company Profile
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The firm is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. The company is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The firm has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Company Info
IPO: 2019-03-18
CYCLERION THERAPEUTICS INC
301 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Peter M. Hecht
Employees: 1
Phone: 16176217722
CYCLERION THERAPEUTICS INC / CYCN FAQ
What does CYCLERION THERAPEUTICS INC do?
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The firm is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. The company is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The firm has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Can you provide the latest stock price for CYCLERION THERAPEUTICS INC?
The current stock price of CYCN is 1.42 USD. The price decreased by -0.7% in the last trading session.
Does CYCLERION THERAPEUTICS INC pay dividends?
CYCN does not pay a dividend.
How is the ChartMill rating for CYCLERION THERAPEUTICS INC?
CYCN has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is CYCN stock listed?
CYCN stock is listed on the Nasdaq exchange.
What is the ownership structure of CYCLERION THERAPEUTICS INC (CYCN)?
You can find the ownership structure of CYCLERION THERAPEUTICS INC (CYCN) on the Ownership tab.
What is the outstanding short interest for CYCLERION THERAPEUTICS INC?
The outstanding short interest for CYCLERION THERAPEUTICS INC (CYCN) is 4.4% of its float.